View More Recent Stories
-
Quest Diagnostics (DGX) PT Raised to $155 at Baird
-
Evercore ISI Resumes Quest Diagnostics (DGX) at In Line
-
Quest Diagnostics (DGX) Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation
-
Quest Diagnostics (DGX) to Acquire University Hospitals' Outreach Laboratory Services Business
-
Quest Diagnostics (DGX) Declares $0.75 Quarterly Dividend; 2% Yield
-
Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Seventh Straight Year
-
Quest Diagnostics (DGX) PT Raised to $150 at Piper Sandler
-
Quest Diagnostics (DGX) PT Raised to $160 at Mizuho
-
Becton Dickinson (BDX) and Quest Diagnostics (DGX) Collaborate to Develop Companion Diagnostics for Cancer, Other Diseases
-
These stocks offer you exposure to rising demand for fertility treatment – Barclays
-
Quest Diagnostics (DGX) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance
-
Life Science Tools & Diagnostics stocks: Q2 earnings preview
-
Quest Diagnostics (DGX) PT Raised to $158 at Truist Securities
-
Quest Diagnostics (DGX) to Acquire Outreach Laboratory Services of OhioHealth
-
Quest Diagnostics (DGX) Price Target Raised to $153 at Truist
-
Quest Diagnostics (DGX) to Acquire LifeLabs from OMERS
-
Quest Diagnostics Releases 2023 Corporate Responsibility Report
-
Quest Diagnostics (DGX) to Acquire Select Lab Assets from Allina Health
-
Citi Reiterates Neutral Rating on Quest Diagnostics (DGX)
-
Quest Diagnostics (DGX) Completes Acquisition of Select PathAI Diagnostics' Lab Assets from PathAI
-
Quest Diagnostics (DGX) Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
-
Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
-
4 Rumors Buzzing Around Wall Street Today
